Featured Research

from universities, journals, and other organizations

Radical treatment for advanced prostate cancer may herald major survival advantage over conventional treatment

Date:
April 14, 2014
Source:
European Association of Urology
Summary:
Controversial new research may overturn the standard treatment of men with advanced prostate cancer. Work indicates that men with advanced prostate cancer could have a better chance of surviving if they undergo treatment directed specifically at the prostate (so-called “radical” therapy) as well as hormonal treatment.

Controversial new research may overturn the standard treatment of men with advanced prostate cancer. Work presented at the European Association of Urology Annual Meeting 2014 indicates that men with advanced prostate cancer could have a better chance of surviving if they undergo treatment directed specifically at the prostate (so-called "radical" therapy) as well as hormonal treatment.

Related Articles


Prostate cancer is the second leading cause of cancer death in Western men. Advanced prostate cancer (where aggressive tumors have spread outside the prostate) usually results in death of the patient. The current standard method of treating advanced prostate cancer is with Androgen Deprivation Therapy (ADT). Androgen hormones, such as testosterone, are known to promote the growth of prostate cancer, and ADT reduces the level of these hormones in the body. Men with advanced prostate cancer who are treated with ADT on average survive around 5 years.

Men with advanced prostate cancer tend not to be offered Radical Prostatectomy (surgery to remove the whole prostate) or Radiotherapy, because their cancer will have already spread outside the primary tumor in the prostate, so ADT has been seen as a better "whole body" solution.

Now, new research from an international team led by Professor Peter Wiklund of the Karolinska Institute in Stockholm may lead to a significant revision of the standard treatment. The team analysed the records from the National Prostate Cancer Registry of Sweden, which contains virtually complete information on more than 98% of all prostate cancer cases in Sweden diagnosed from 1996 to 2010 -- more than 109,000 men. From this database, they selected 2 groups of 699 men, which differed only in whether they had been offered ADT as a first treatment, or if they had first been treated by radical prostatectomy or radiotherapy followed by ADT.

They found almost two and a half times the number of deaths from prostate cancer in the group who had first been offered the standard hormonal treatment, in comparison to those who had undergone prostate-removing surgery prior to hormone treatment. After 14 years follow up, 231 of those treated with hormones alone had died of prostate cancer, whereas only 93 of those treated with the surgery or radiotherapy plus hormones had died of prostate cancer.

When they compared total deaths in the two groups, they found that twice as many men had died after hormone treatment (321), than with the combined treatment (155).

Presenting the work at the European Association of Urology in Stockholm, Dr Prasanna Sooriakumaran of the University of Oxford said:

"We found that men with advanced prostate cancer have significantly improved survival after radical therapy plus hormonal treatment compared to hormonal treatment alone. We performed sensitivity tests to check that these results were unlikely to be due to abnormalities or deficiencies in the dataset, so we are confident in these results. This means we need to test these findings in a controlled study.

Currently, men with advanced prostate cancer are treated with hormonal therapy alone, and the median survival is around 5 years. A number of novel agents have been proposed in recent years, and these improve survival by months. Our research has the potential to improve survival outcomes by more than these novel treatments, and thus could represent a major advance in the field."

Professor Peter Wiklund further commented: "What we are presenting here is not only new but highly controversial, and will represent a paradigm shift in our understanding and management of advanced prostate cancer. Should the improved survival that combined treatment shown in this study be a real effect, then this could revolutionize the management of advanced prostate cancer. Our next step is to perform a multicenter randomized controlled trial to evaluate this question with the highest level evidence."

EAU Secretary General, Per-Anders Abrahamsson (Malmo) added: "This is potentially very important work, and needs to be followed up. If a larger trial confirms these results then it will be a major advance in the treatment of advanced prostate cancer"


Story Source:

The above story is based on materials provided by European Association of Urology. Note: Materials may be edited for content and length.


Cite This Page:

European Association of Urology. "Radical treatment for advanced prostate cancer may herald major survival advantage over conventional treatment." ScienceDaily. ScienceDaily, 14 April 2014. <www.sciencedaily.com/releases/2014/04/140414091905.htm>.
European Association of Urology. (2014, April 14). Radical treatment for advanced prostate cancer may herald major survival advantage over conventional treatment. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2014/04/140414091905.htm
European Association of Urology. "Radical treatment for advanced prostate cancer may herald major survival advantage over conventional treatment." ScienceDaily. www.sciencedaily.com/releases/2014/04/140414091905.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins